BRAF News

News

Addition of Targeted Therapy Induction Phase to Combined Immunotherapy for Patients with BRAF-V600E/K Mutant Melanoma

06/20/2024

Allison Casey

According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.

According to a phase 2 study,...

06/20/2024

Oncology

News

First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs VEGF Inhibitors

03/26/2022

Alexa Stoia

Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.

Pashtoon M. Kasi, MD, MS, argued...

03/26/2022

Oncology

Conference Insider

Vemurafenib Beneficial for Nonmelanoma Cancers With BRAF V600 Mutations

09/19/2020

Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma cancers.

Study data presented by Pascale...

09/19/2020

Oncology

News

FDA Approves Atezolizumab Combo for BRAF V600+ Melanoma

08/03/2020

The FDA has approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

The FDA has approved...

08/03/2020

Oncology

News

Meta-Analysis Supports Consideration of MSI Status in BRAF V600E-Positive CRC

01/14/2020

Meta-analysis findings suggest that MSI status should be considered as a stratification factor for better management of patients with BRAF V600E-positive CRC.

Meta-analysis findings suggest...

01/14/2020

Oncology

News

Triplet Regimen Significantly Improves OS in BRAF V600E-Mutated Metastatic CRC

10/18/2019

Encorafenib, combined with cetuximab and binimetinib resulted in significantly longer OS and a higher response rate compared with standard therapy in patients with metastatic CRC harboring the BRAF v600E mutation.

Encorafenib, combined with...

10/18/2019

Oncology

News

Combined BRAF and MEK Inhibition Offers Survival Benefit in Melanoma

08/29/2019

Combined BRAF/MEK inhibition improved survival in patients with metastatic melanoma, despite GI toxicities.

Combined BRAF/MEK inhibition...

08/29/2019

Oncology

News

Incidence of Microsatellite Instability in Metastatic CRC High, Tied to Worse Survival

06/13/2019

Results from a recent study of patients with metastatic CRC suggest that immunotherapy should be considered as first-line treatment in those with MSI-H tumors.

Results from a recent study of...

06/13/2019

Oncology

News

Baseline Prognostic Factors for Metastatic Melanoma With BRAF V600 Mutation

08/08/2018

Baseline lactate dehydrogenase level, performance status, disease burden, and gene signature are key factors for determining the survival outcomes of patients with BRAF V600 mutation–positive metastatic melanoma.

Baseline lactate dehydrogenase...

08/08/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology